<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Koren, Michael J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tolvaptan Did Not Reduce Hospital Stay for Hyponatremia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Hyponatremia is the most common clinically encountered serum electrolyte abnormality, occurring in 7% to 8% of elderly, ambulatory patients and 15% to 20% of hospitalized patients [Huda MS et al. Postgrad Med J 2006]. This article reports on a prospective clinical trial that evaluated the effect of the selective, competitive vasopressin 2 antagonist tolvaptan in the treatment of hyponatremia [Koren MJ et al. ICE ENDO 2014 (poster LBSA-0737)].</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>